Psychiatr Serv 56:157-163, February 2005
© 2005 American Psychiatric Association
Effect of Medicaid Eligibility Category on Racial Disparities in the Use of Psychotropic Medications Among Youths
Julie Magno Zito, Ph.D.,
Daniel J. Safer, M.D.,
Ilene H. Zuckerman, Pharm.D.,
James F. Gardner, Sc.M. and
Karen Soeken, Ph.D.
OBJECTIVE: This study sought to determine the degree to which Medicaid eligibility categories modify disparities between black and white youths in the prevalence of psychotropic medication. METHODS: Computerized claims for 189,486 youths aged two to 19 years who were continuously enrolled in a mid-Atlantic state Medicaid program for the year 2000 were analyzed to determine population-based annual prevalence of psychotropic medication by race or ethnicity and by whether the youths were eligible for Medicaid for reasons of family income, disability, or foster care placement. Logistic regression was used to assess the interaction of eligibility category and race. RESULTS: The mean annual prevalence of psychotropic medication for the population was 9.9 percent. The prevalence was 2.17 times higher for white youths than for black youths (16.5 percent compared with 7.6 percent). However, within eligibility categories, the white-to-black disparity was 3.8 among youths who were eligible for Medicaid because their family income was below the federal poverty level and 3.2 for youths enrolled in the State Children's Health Insurance Program. CONCLUSIONS: Medicaid eligibility categories had a profound impact on the racial disparity associated with the prevalence of psychotropic medications for youths. Eligibility category should be taken into account when ascertaining the role of access, undertreatment, and culture in disparities in mental health treatment.
This article has been cited by other articles:
|
|
|
|
 
D. S. Mandell, K. H. Morales, S. C. Marcus, A. C. Stahmer, J. Doshi, and D. E. Polsky
Psychotropic Medication Use Among Medicaid-Enrolled Children With Autism Spectrum Disorders
Pediatrics,
March 1, 2008;
121(3):
e441 - e448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Zito, D. J. Safer, D. Sai, J. F. Gardner, D. Thomas, P. Coombes, M. Dubowski, and M. Mendez-Lewis
Psychotropic Medication Patterns Among Youth in Foster Care
Pediatrics,
January 1, 2008;
121(1):
e157 - e163.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Stein, J. N. Kogan, M. J. Sorbero, W. Thompson, and S. L. Hutchinson
Predictors of Timely Follow-Up Care Among Medicaid-Enrolled Adults After Psychiatric Hospitalization
Psychiatr Serv,
December 1, 2007;
58(12):
1563 - 1569.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Clark, M. Samnaliev, and M. P. McGovern
Treatment for Co-occurring Mental and Substance Use Disorders in Five State Medicaid Programs
Psychiatr Serv,
July 1, 2007;
58(7):
942 - 948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wang, J. M. Noel, I. H. Zuckerman, N. A. Miller, F. T. Shaya, and C. D. Mullins
Disparities in Access to Essential New Prescription Drugs between Non-Hispanic Whites, Non-Hispanic Blacks, and Hispanic Whites.
Med Care Res Rev,
December 1, 2006;
63(6):
742 - 763.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Olfson, C. Blanco, L. Liu, C. Moreno, and G. Laje
National trends in the outpatient treatment of children and adolescents with antipsychotic drugs.
Arch Gen Psychiatry,
June 1, 2006;
63(6):
679 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Zito, D. J. Safer, J. F. Gardner, K. Soeken, and J. Ryu
Anticonvulsant Treatment for Psychiatric and Seizure Indications Among Youths
Psychiatr Serv,
May 1, 2006;
57(5):
681 - 685.
[Abstract]
[Full Text]
[PDF]
|
|
|
Get information about faster international access.
Privacy Policy
Copyright © 2005
American Psychiatric Association.
All rights reserved.
Home
| Search
| Current Issue
| Past Issues
| Subscribe
| All APPI Journals
| Help
| Contact Us
|
